Alkermes plc (NASDAQ: ALKS) Sees Executive Share Sale Amid Growth

Alkermes plc (NASDAQ: ALKS) is advancing in the neuroscience and oncology sectors, with significant developments in sleep medicine.Executive VP Craig C. Hopkinson sold 5,000 shares, remaining with 61,740 shares, amidst the company's financial growth highlighted by a 32% increase in Lybalvi sales.The company's stock price reflects a modest increase, supported by a strong market capitalization and trading volume, alongside promising clinical trial results for Alixorexton.Alkermes plc (NASDAQ: ALKS) is a bioph ...